Maria Trojano Selected Research

Relapsing-Remitting Multiple Sclerosis

2/2022	Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
1/2022	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
12/2021	A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
12/2021	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
11/2021	Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
11/2021	Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
11/2021	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
8/2021	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies.
1/2021	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
1/2021	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Trojano Research Topics

Disease

121	Multiple Sclerosis 11/2022 - 08/2002
40	Relapsing-Remitting Multiple Sclerosis 02/2022 - 10/2003
9	COVID-19 07/2022 - 01/2020
9	Neuromyelitis Optica (Devic's Disease) 01/2021 - 10/2009
8	Cognitive Dysfunction 01/2019 - 10/2004
6	Demyelinating Diseases (Demyelinating Disease) 01/2018 - 02/2004
5	Fatigue 04/2021 - 01/2012
4	Progressive Multifocal Leukoencephalopathy 02/2022 - 08/2014
4	Chronic Progressive Multiple Sclerosis 11/2021 - 01/2016
4	Disease Progression 09/2021 - 04/2007
3	Autoimmune Diseases (Autoimmune Disease) 12/2020 - 01/2003
3	Spontaneous Abortion (Miscarriage) 02/2019 - 10/2012
3	Inflammation (Inflammations) 07/2014 - 04/2007
2	Neuroinflammatory Diseases 01/2022 - 01/2019
2	Pain (Aches) 01/2016 - 01/2014
2	Spasm (Spasms) 01/2016 - 01/2014
1	Edema (Dropsy) 02/2022
1	Brain Edema (Cerebral Edema) 02/2022
1	Glioblastoma (Glioblastoma Multiforme) 02/2022
1	Neoplasms (Cancer) 02/2022
1	Meningitis 01/2022
1	Infections 01/2022
1	Muscular Diseases (Myopathy) 01/2022
1	Opportunistic Infections (Opportunistic Infection) 01/2022
1	Prodromal Symptoms 01/2022
1	Dengue (Dengue Fever) 11/2021
1	Shock 11/2021
1	Guillain-Barre Syndrome 10/2021
1	Papilledema 09/2021
1	Atypical Hemolytic Uremic Syndrome 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2020
1	Sudden Infant Death (SID) 12/2020
1	Glycogen Storage Disease Type VI (Glycogenosis Type VI) 05/2020
1	Autosomal Dominant Optic Atrophy (Dominant Optic Atrophy) 04/2020

Drug/Important Bio-Agent (IBA)

30	Natalizumab (Tysabri)FDA Link 11/2022 - 12/2011
19	Fingolimod Hydrochloride (FTY720)FDA Link 02/2022 - 04/2014
18	InterferonsIBA 01/2022 - 07/2003
15	Interferon-betaIBA 01/2022 - 10/2003
12	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 01/2007
7	Dimethyl FumarateIBA 02/2022 - 01/2019
7	AutoantibodiesIBA 01/2021 - 10/2009
6	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2004
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
6	Immunoglobulin G (IgG)IBA 01/2021 - 10/2009
6	Dronabinol (THC)FDA LinkGeneric 01/2016 - 01/2014
5	Protein Isoforms (Isoforms)IBA 02/2022 - 09/2002
5	teriflunomideIBA 02/2022 - 01/2019
5	AntibodiesIBA 01/2022 - 07/2003
5	Cladribine FDA LinkGeneric 01/2022 - 10/2018
4	ocrelizumabIBA 11/2021 - 01/2020
4	Messenger RNA (mRNA)IBA 01/2018 - 07/2005
4	Interferon beta-1a FDA Link 01/2017 - 03/2009
4	Pharmaceutical PreparationsIBA 01/2016 - 05/2014
4	Neutralizing AntibodiesIBA 01/2016 - 05/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 07/2014
3	Monoclonal AntibodiesIBA 11/2021 - 10/2009
3	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2018
3	CannabidiolIBA 01/2016 - 01/2015
2	Methylprednisolone FDA LinkGeneric 07/2022 - 01/2021
2	TabletsIBA 01/2022 - 01/2020
2	Oxidoreductases (Dehydrogenase)IBA 01/2022 - 04/2007
2	VaccinesIBA 11/2021 - 09/2021
2	Cytidine Diphosphate (CDP)IBA 01/2021 - 01/2018
2	Rituximab (Mabthera)FDA Link 01/2021 - 01/2020
2	nitazoxanide (NTZ)FDA Link 12/2020 - 01/2012
2	Alemtuzumab (Campath)FDA Link 01/2020 - 01/2017
2	Transcription Factors (Transcription Factor)IBA 11/2018 - 04/2007
2	SuspensionsIBA 01/2018 - 11/2015
2	Aquaporins (Water Channels)IBA 01/2018 - 10/2009
2	Oligoclonal BandsIBA 01/2018 - 01/2004
2	OsteopontinIBA 01/2014 - 06/2005
2	N-acetylaspartate (N-acetyl aspartate)IBA 07/2012 - 02/2012
2	CytokinesIBA 06/2005 - 01/2003
1	Fluorescein (Funduscein)FDA LinkGeneric 02/2022
1	Air Pollutants (Pollutants, Air)IBA 01/2022
1	ArginaseIBA 01/2022
1	Coenzyme A (CoA)IBA 01/2022
1	Ligases (Synthetase)IBA 01/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2022
1	Signal Recognition ParticleIBA 01/2022
1	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 01/2022
1	Particulate MatterIBA 01/2022
1	CD20 AntigensIBA 11/2021
1	Vasopressins (Vasopressin)IBA 10/2021
1	ChAdOx1 nCoV-19IBA 09/2021
1	Starch SynthaseIBA 09/2021
1	Influenza Vaccines (Influenza Vaccine)FDA Link 04/2021
1	PlatinumIBA 01/2021
1	eculizumab FDA Link 01/2021
1	nomegestrol acetateIBA 01/2021
1	Glycoproteins (Glycoprotein)IBA 01/2021
1	SteroidsIBA 01/2021
1	Cyclic AMP (AMP, Cyclic)IBA 12/2020
1	durvalumabIBA 12/2020

Therapy/Procedure

63	Therapeutics 10/2022 - 06/2008
7	Injections 02/2022 - 03/2015
5	Immunotherapy 01/2021 - 01/2017
4	Immunomodulation 01/2021 - 04/2016
1	Secondary Prevention 01/2022
1	Precision Medicine 09/2021